Study drug for active dermatomyositis or polymyositis
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult age 18 or older.
- You have active dermatomyositis or polymyositis that started when you were younger (age of onset required).
- You are on a steady (not changing) dose of standard care medicines at the time you enroll.
- Your muscle disease is idiopathic inflammatory myopathy (not caused by other specific myositis types).
- You do not have certain serious infections or recent hospitalization for serious infection within the last 60 days.
- You do not have recent or current cancer (within 5 years), major recent heart/stroke events, certain major surgeries, or high-risk immune/neurologic conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
This trial tests whether a drug called maraviroc, which is usually used for HIV, can also reduce inflammation in people with myositis. It is for patients whose myositis is still active despite taking multiple standard treatments.
This trial tests a new drug called nerandomilast in people with active inflammatory muscle disease (myositis) that is not well controlled with current treatments. It aims to see if the drug can improve muscle strength and overall disease activity.
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
This study is testing an experimental medicine called PF-08154225 to see if it can help treat several autoimmune conditions, including rheumatoid arthritis, lupus, and related disorders. It might reduce disease activity or symptoms in people who have not found relief from other treatments.
This trial tests a new medicine called NM8074 for people with dermatomyositis, a condition that causes muscle weakness and skin rash. The goal is to see if it can help reduce symptoms.
Hear when a new Myositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.